Who are Praxis's investors?

Praxis's investors include Avoro Capital Advisors, Capria Ventures, OCV Partners, Alameda Research, Norwest Venture Partners, Three Arrows Capital.

Praxis

6 known investors

praxismedicines.com ↗

Praxis Precision Medicines is a central nervous system precision neuroscience biopharmaceutical company developing therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance, with a pipeline spanning movement disorders and epilepsy. Its portfolio uses both small molecule (Cerebrum) and antisense oligonucleotide (Solidus) platforms informed by human genetics and translational science.</parameter> <parameter name="founders">[]

BiotechDeep TechHealthtech

Investors · 6

Avoro Capital AdvisorsNew York

Capria VenturesBengaluru · $300K – $1M

OCV PartnersLos Angeles

Alameda ResearchreportedCentral and Western · $1.3M – $35M

Norwest Venture PartnersreportedMenlo Park · $10M – $30M

Three Arrows Capitalreported

Founder mafia

2 people who came through Praxis went on to found or lead other companies.

Jill DeSimoneIndependent Board DirectorFounded Indegene Carlos LoyaGlobal Commercial LeadFounded Aldebaran Therapeutics

In the news

The "Network State" project Praxis raises $525 million, and the blockchain version of utopia still faces numerous challenges｜Praxis, Arch Lending - ChainCatcherchaincatcher.com · Oct 2024

Praxis Raises $15M in Series A Funding Roundfinance.yahoo.com · Mar 2022

Praxis Labs Raises $15.5M in Series A Funding - FinSMEsfinsmes.com · Oct 2021

Praxis Labs Raises $15.5M in Oversubscribed Series A Led by Norwest Venture Partners and Emerson Collectiveprnewswire.com · Oct 2021

Praxis Labs Raises $3.2M in Seed Funding - FinSMEsfinsmes.com · Feb 2021

Elise Smith, CEO Of Praxis Labs, Raises $3.2 Million In Venture Capital To Help Bring Forth More Conscious Leaders Using Virtual Realityforbes.com · Feb 2021

Frequently asked questions

What does Praxis do?: Praxis Precision Medicines is a central nervous system precision neuroscience biopharmaceutical company developing therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance, with a pipeline spanning movement disorders and epilepsy. Its portfolio uses both small molecule (Cerebrum) and antisense oligonucleotide (Solidus) platforms informed by human genetics and translational science.</parameter> <parameter name="founders">[]
Who are Praxis's investors?: Praxis's investors include Avoro Capital Advisors, Capria Ventures, OCV Partners, Alameda Research, Norwest Venture Partners, Three Arrows Capital.